Skip to main content
. Author manuscript; available in PMC: 2018 Aug 9.
Published in final edited form as: Neuropharmacology. 2017 Aug 26;134(Pt A):46–56. doi: 10.1016/j.neuropharm.2017.08.033

Fig. 3.

Fig. 3

Effects of MeCa ± L-DOPA, PARG or METH on markers of striatal dopaminergic toxicity. Levels of (A) DA, (B) DAT, and (C) TH were determined in the striatum following treatment with MeCa, +/−L-DOPA (L–D), pargyline (PARG), or METH. *p < 0.05 **p < 0.01 ***p < 0.001 ****p < 0.0001 compared to controls. #p < 0.05 ##p < 0.01 compared to MeCa. Data are presented as mean + SEM. N = 5–16 mice per group.